The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised






About Ulthera

Ulthera develops and markets medical devices that leverage the proven power and safety of ultrasound for rejuvenation of the skin and its support structure. Ultherapy treatments enable dermatologists, plastic surgeons and facial plastic surgeons, for a time, to non-invasively see and treat deep below the skin, resulting in precision and predictability.

Ulthera Headquarter Location

2150 South Country Club Drive Suite 27

Mesa, Arizona, 85210,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ulthera

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ulthera is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Ulthera Patents

Ulthera has filed 59 patents.

The 3 most popular patent topics include:

  • Plastic surgery
  • Medical ultrasonography
  • Medical equipment
patents chart

Application Date

Grant Date


Related Topics




Plastic surgery, Rare diseases, Medical equipment, Medical treatments, Ultrasound


Application Date


Grant Date



Related Topics

Plastic surgery, Rare diseases, Medical equipment, Medical treatments, Ultrasound



Latest Ulthera News

The Worldwide Dermal Facial Fillers Industry is Expected to Reach $4.75 Billion by 2027 -

Feb 18, 2022

Syneron Medical Ltd. (Candela Laser Corporation) Ulthera Inc. Visionmed Ltd. Keeping in mind the uncertainties of COVID-19, they are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor A dermal facial filler is an injectable solution which fills the soft tissue present under the skin. Dermal fillers can be both synthetic and natural. With age, the flexibility of the skin is lost along with the natural hydration which helps in shaping, supporting and adding volume to the face. This phenomenon results in the occurrence of wrinkles and sagging of the skin. Dermal fillers are applied through tiny facial injections to specific areas of the face. They raise and pump the facial skin in a gentle manner by replacing the collagen lost due to the above factors. Dermal fillers are helpful in enhancing the appearance of aging, wrinkling and sagging skin. They are used in the form of a non-invasive treatment to rejuvenate facial skin by minimising or removing wrinkles, raising depressions caused by scars, augmenting lips, and replacing the lost soft-tissue through facial injections The dermal facial fillers market is strongly being driven by an increase in the number of people seeking treatment for facial wrinkles and scarring. This increase has occurred on account of a continuous rise in an imbalance diet, stress and insomnia. Another major driver of this market is the fact that this treatment is non-invasive and has does not take a long period of time to be conducted. Moreover, there has been a decrease in the number of complexities which occur post-surgery. In addition to this, the surgery does not have a prominent scarring as it requires very small incisions which has positively influenced the overall growth of the market. Other factors that are catalysing the growth of this market include a rising ageing population, increasing disposable incomes and raising awareness through social media platforms such as youtube and Instagram Key Questions Answered in This Report: How has the global dermal facial fillers market performed so far and how will it perform in the coming years? What are the key regional markets in the global dermal facial fillers industry? What has been the impact of COVID-19 on the global dermal facial fillers market? What is the major product origin in the global dermal facial fillers industry? What is the major material types in the global dermal facial fillers industry? What are the various stages in the value chain of the global dermal facial fillers market? What are the key driving factors and challenges in the global dermal facial fillers market? What is the structure of the global dermal facial fillers market and who are the key players? What is the degree of competition in the global dermal facial fillers market? Key Topics Covered:

  • When was Ulthera founded?

    Ulthera was founded in 2004.

  • Where is Ulthera's headquarters?

    Ulthera's headquarters is located at 2150 South Country Club Drive, Mesa.

  • What is Ulthera's latest funding round?

    Ulthera's latest funding round is Acquired.

  • How much did Ulthera raise?

    Ulthera raised a total of $38.56M.

  • Who are the investors of Ulthera?

    Investors of Ulthera include Merz Therapeutics, New Enterprise Associates, Apposite Capital, 3i Group and Ardent Sound.

  • Who are Ulthera's competitors?

    Competitors of Ulthera include Integrated Nano-Technologies, iMMCO Diagnostics, Cutera, ContraVac, Novadaq Technologies and 11 more.

You May Also Like


Affinergy develops site-specific biological delivery systems using biofriendly binders that can selectively adhere to proteins, cells and other biomaterial surfaces. Affinergy's multifunctional delivery systems offer unprecedented opportunities to target therapeutic delivery, functionalize medical devices, and enable a variety of diagnostic and biosensor applications. Affinergy is a Duke University spin-out company being incubated by BD (Becton, Dickinson and Company) and is headquartered in Research Triangle Park, NC. IDEA Fund Partners was an investor in the company's Series A financing.

Akonni Biosystems Logo
Akonni Biosystems

Akonni Biosystems is a molecular diagnostics (MDx) company that develops, manufactures, and markets integrated molecular diagnostic systems.


UIQI2 is designed to develop and utilize in-house processes and technical infrastructure for the conduct of imaging-based multi-center trials. The main objective is to develop infrastructure within the University of Iowa, which will support the pulmonary imaging portion of government and industry-based multi-center trials. The target audience is government and corporate sponsored multi-centered pre-clinical and clinical trials; specifically the Pharmaceutical and Device sectors of the medical industry as well as large NIH trials.

Integrated Nano-Technologies

Integrated Nano-Technologies specializes in developing creative solutions for diagnostic sample processing, and provides field personnel with fast, accurate test results that can improve biological identification.


Focal develops, manufactures and commercializes synthetic, absorbable, liquid surgical sealants based on the company's polymer technology. The company's FocalSeal-L and FocalSeal-S surgical sealant products are currently being developed for use inside the body to seal leaks resulting from lung, neurological, cardiovascular and gastrointestinal surgery.

Sober Steering Logo
Sober Steering

Sober Steering develops transdermal technologies as means for detecting driver intoxication.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.